Hematological Side Effects of Co-trimoxazole

Overview

Journal Infection

Date 1987 Jan 1

PMID 3325435

Citations 17

Authors

H Heimpel

A Raghavachar

Affiliations

Soon will be listed here.

Abstract

Decrease of blood cells may be induced by either components of co-trimoxazole. Side effects of the trimethoprim component are much more frequent, particularly in risk groups. They are dose dependent, usually not severe, only rarely of clinical significance and easily treated or prevented by folate supplementation. In contrast, side effects of the sulfamethoxazole component seem to be extremely rare. They are similar to the hematological side effects of other sulfonamide drugs. They are idiosyncratic, nonpredictable and mostly mediated by the immune-system. They may be of life-threatening severity and no therapy is known except termination of exposure and supportive measures such as substitution of blood cells and antiinfectious therapy by non-related antibiotics.

Citing Articles

Benzenesulfonohydrazide-tethered non-fused and fused heterocycles as potential anti-mycobacterial agents targeting enoyl acyl carrier protein reductase (InhA) with antibiofilm activity.

Al-Warhi T, Sabt A, Korycka-Machala M, Kassem A, Shaldam M, Abdelsattar Ibrahim H RSC Adv. 2024; 14(41):30165-30179.

PMID: 39315015 PMC: 11418391. DOI: 10.1039/d4ra05616g.

Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy.

Shan W, Wang L, Qin J, Peng W, Ma K Infect Drug Resist. 2024; 17:2299-2306.

PMID: 38868399 PMC: 11168416. DOI: 10.2147/IDR.S461206.

Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.

Gottesdiener L, Satlin M Transpl Infect Dis. 2023; 25 Suppl 1:e14169.

PMID: 37864309 PMC: 10844985. DOI: 10.1111/tid.14169.

Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives.

Angelova V, Pencheva T, Vassilev N, K-Yovkova E, Mihaylova R, Petrov B Antibiotics (Basel). 2022; 11(5).

PMID: 35625207 PMC: 9137698. DOI: 10.3390/antibiotics11050562.

The Relationship of Drug Therapy to Aplastic Anemia in Pakistan: A Hospital-Based Case Control Study.

Syed M, Rahman A, Shah Syed M, Memon N Ther Clin Risk Manag. 2021; 17:903-908.

PMID: 34475759 PMC: 8407775. DOI: 10.2147/TCRM.S325742.

References

Sive J, Green R, Metz J . Effect of trimethoprim on folate-dependent DNA synthesis in human bone marrow. J Clin Pathol. 1972; 25(3):194-7. PMC: 477261. DOI: 10.1136/jcp.25.3.194. View

Bow E, Louie T, Riben P, McNaughton R, Harding G, Ronald A . Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am J Med. 1984; 76(2):223-33. DOI: 10.1016/0002-9343(84)90777-0. View

Rubin R, SWARTZ M . Trimethoprim-sulfamethoxazole. N Engl J Med. 1980; 303(8):426-32. DOI: 10.1056/NEJM198008213030804. View

Dekker A, Rozenberg-Arska M, Sixma J, Verhoef J . Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med. 1981; 95(5):555-9. DOI: 10.7326/0003-4819-95-5-555. View

Kelton J, Meltzer D, Moore J, Giles A, Wilson W, Barr R . Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro. Blood. 1981; 58(3):524-9. View

Principi N, Marchisio P, Biasini A, Dalla Villa A, Biasini G . Early and late neutropenia in children treated with cotrimoxazole (trimethoprim-sulfamethoxazole). Acta Paediatr Scand. 1984; 73(6):763-7. DOI: 10.1111/j.1651-2227.1984.tb17772.x. View

Bose W, Karama A, LINZENMEIER G, OLBING H, Wellmann P . Controlled trial of co-trimoxazole in children with urinary-tract infection. Bacteriological efficacy and haematological toxicity. Lancet. 1974; 2(7881):614-6. DOI: 10.1016/s0140-6736(74)91941-2. View

Poskitt E, PARKIN J . Effect of trimethoprim-sulphamethoxazole combination on folate metabolism in malnourished children. Arch Dis Child. 1972; 47(254):626-30. PMC: 1648303. DOI: 10.1136/adc.47.254.626. View

Kurrle E, Bhaduri S, Krieger D, Pflieger H, Heimpel H . Antimicrobial prophylaxis in acute leukaemia: prospective randomized study comparing two methods of selective decontamination. Klin Wochenschr. 1983; 61(14):691-8. DOI: 10.1007/BF01487614. View

10.

Kovacs J, Hiemenz J, Macher A, Stover D, Murray H, Shelhamer J . Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984; 100(5):663-71. DOI: 10.7326/0003-4819-100-5-663. View

11.

Claas F, van der Meer J, Langerak J . Immunological effect of co-trimoxazole on platelets. Br Med J. 1979; 2(6195):898-9. PMC: 1596719. DOI: 10.1136/bmj.2.6195.898. View

12.

. Letter: Co-trimoxazole and the blood. Lancet. 1974; 1(7863):929-30. DOI: 10.1016/s0140-6736(74)90378-x. View

13.

MIESCHER P, Graf J . Drug-induced thrombocytopenia. Clin Haematol. 1980; 9(3):505-19. View

14.

Dickson H . Trimethoprim-sulphamethoxazole and thrombocytopenia. Med J Aust. 1978; 2(1):5-7. DOI: 10.5694/j.1326-5377.1978.tb131300.x. View

15.

Jewkes R, Edwards M, Grant B . Haematological changes in a patient on long-term treatment with a trimethoprim-sulphonamide combination. Postgrad Med J. 1970; 46(542):723-6. PMC: 2467130. DOI: 10.1136/pgmj.46.542.723. View

16.

Tschan M, Neuhaus K . [Bone-marrow damage by medicaments: diagnostic, therapeutic and prophylactic measurements (author's transl)]. Schweiz Rundsch Med Prax. 1978; 67(31):1124-8. View

17.

STEBBINS R, Bertino J . Megaloblastic anaemia produced by drugs. Clin Haematol. 1976; 5(3):619-30. View

18.

Scott J, Weir D . Drug-induced megaloblastic change. Clin Haematol. 1980; 9(3):587-606. View

19.

Lennon D . Co-trimoxazole toxicity. Lancet. 1984; 2(8412):1152. DOI: 10.1016/s0140-6736(84)91579-4. View

20.

INMAN W . Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J. 1977; 1(6075):1500-5. PMC: 1607252. DOI: 10.1136/bmj.1.6075.1500. View